{
    "organizations": [],
    "uuid": "b4b31ae65c33af04a38ace92147d16fd7ffcd7b9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-european-medicines-agencyissues-or/brief-european-medicines-agencyissues-orphan-drug-designation-positive-opinion-for-omeros-oms721-idUSFWN1PH0MU",
    "ord_in_thread": 0,
    "title": "BRIEF-European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 22 (Reuters) - Omeros Corp:\n* EUROPEAN MEDICINES AGENCY ISSUES ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR OMEROSâ€™ OMS721 IN THE TREATMENT OF IGA NEPHROPATHY\n* OMEROS CORP - EMA ALSO REVIEWING PRIORITY MEDICINES APPLICATION FOR DRUG IN IGAN\n* OMEROS CORP - POSITIVE OPINION ISSUED BY COMP IS EXPECTED TO BE ADOPTED BY EUROPEAN COMMISSION AT ITS FEBRUARY MEETING Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-22T20:17:00.000+02:00",
    "crawled": "2018-01-23T18:19:41.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "omeros",
        "corp",
        "european",
        "medicine",
        "agency",
        "issue",
        "orphan",
        "drug",
        "designation",
        "positive",
        "opinion",
        "omeros",
        "oms721",
        "treatment",
        "iga",
        "nephropathy",
        "omeros",
        "corp",
        "ema",
        "also",
        "reviewing",
        "priority",
        "medicine",
        "application",
        "drug",
        "igan",
        "omeros",
        "corp",
        "positive",
        "opinion",
        "issued",
        "comp",
        "expected",
        "adopted",
        "european",
        "commission",
        "february",
        "meeting",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}